Article Data

  • Views 872
  • Dowloads 130

Original Research

Open Access

Analysis of the preliminary findings of rivaroxaban plus Danshen polyphenolic acid in the treatment of patients with atrial fibrillation during the recovery period of cardiogenic cerebral infarction

  • Dejuan Zhang1
  • Chao Yan2,*,

1Three Departments of General Medicine, Second People’s Hospital of Anhui Province, 230031 Hefei, Anhui, China

2Departments of Critical Care Medicine, Second People’s Hospital of Anhui Province, 230031 Hefei, Anhui, China

DOI: 10.22514/sv.2024.074 Vol.20,Issue 6,June 2024 pp.78-85

Submitted: 20 February 2024 Accepted: 10 May 2024

Published: 08 June 2024

*Corresponding Author(s): Chao Yan E-mail: c_yanc1222@163.com

Abstract

This study aimed at exploring the clinical efficacy of rivaroxaban plus Danshen polyphenolic acid for treating atrial fibrillation in patients recuperating from cardiogenic cerebral infarction. The data of 80 patients with atrial fibrillation in the recovery phase (subacute rehabilitation stage) of cardiogenic cerebral infarction, who underwent treatment at the Second People’s Hospital of Anhui Province between January 2020 and October 2023, were retrieved and assessed. They were randomly divided into two groups (a control and study group; 40 cases/group) using the random number table method. The control group received anticoagulant treatment with rivaroxaban, while the study group received a combination of rivaroxaban and Danshen polyphenolic acid. Then, the symptom scores, neutrophil-to-lymphocyte ratio (NLR), coagulation function indicators, vascular endothelial function indicators, and adverse reactions between the two groups of patients were compared and analyzed. Before treatment, there were no significant differences observed in The National Institute of Health Stroke Scale (NIHSS) score, D-Dimer (D-D), fibrinogen (FIB), antithrombin-III (AT-III), C-reactive protein (CRP), and soluble intercellular adhesion molecule-1 (sICAM-1) between the two groups (p > 0.05). After treatment, both groups exhibited a significant reduction in NIHSS scores, D-D, FIB, CRP and sICAM-1 levels, with the study group demonstrating significantly lower values compared to the control group (p < 0.05). Moreover, after treatment, both groups had a significant increase in AT-III levels, with the study group exhibiting significantly higher levels than the control group (p < 0.05). The incidence of adverse reactions in the study group was 5.00%, significantly lower than the 20.00% observed in the control group (p < 0.05). We conclude that, using rivaroxaban plus Danshen polyphenolic acid for treating patients with atrial fibrillation during the recovery phase of cardiogenic cerebral infarction could effectively enhance coagulation function, diminish inflammatory response status, facilitate symptom recovery, and enhance clinical prognosis.


Keywords

Rivaroxaban; Danshen polyphenolic acid; Cardiogenic cerebral infarction; Atrial fibrillation; Clinical efficacy


Cite and Share

Dejuan Zhang,Chao Yan. Analysis of the preliminary findings of rivaroxaban plus Danshen polyphenolic acid in the treatment of patients with atrial fibrillation during the recovery period of cardiogenic cerebral infarction. SignaVitae. 2024. 20(6);78-85.

References

[1] Karthikeyan G, Connolly SJ, Yusuf S. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. Reply. The New England Journal of Medicine. 2022; 387: 2100–2101.

[2] Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A, et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. The New England Journal of Medicine. 2022; 387: 978–988.

[3] Gu HQ. Rivaroxaban vs apixaban and ischemic or hemorrhagic events in patients with atrial fibrillation. JAMA Network. 2022; 327: 1290.

[4] Galiuto L, Patrono C. Rivaroxaban, a novel option for patients with atrial fibrillation and a bioprosthetic mitral valve. European Heart Journal. 2021; 42: 811–812.

[5] Ray WA, Chung CP, Stein CM, Smalley W, Zimmerman E, Dupont WD, et al. Risk for bleeding-related hospitalizations during use of amiodarone with apixaban or rivaroxaban in patients with atrial fibrillation. Annals of Internal Medicine. 2023; 176: 769–778.

[6] Cong S, Dong C, Hu Y, Wang C, Zhang B, Li N. Effect of salvia miltiorrhiza polyphenolic acid injection on improving limb use and cognitive impairment in patients with acute stroke. Computational and Mathematical Methods in Medicine. 2022; 2022: 1481294.

[7] Fu EL, Desai RJ, Paik JM, Kim DH, Zhang Y, Mastrorilli JM, et al. Comparative safety and effectiveness of warfarin or rivaroxaban versus apixaban in patients with advanced CKD and atrial fibrillation: nationwide us cohort study. American Journal of Kidney Diseases. 2024; 83: 293–305.e1.

[8] De Vriese AS, Caluwé R, Van Der Meersch H, De Boeck K, De Bacquer D. Safety and efficacy of vitamin k antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. Journal of the American Society of Nephrology. 2021; 32: 1474–1483.

[9] Naito R, Miyauchi K, Yasuda S, Kaikita K, Akao M, Ako J, et al. Rivaroxaban monotherapy vs combination therapy with antiplatelets on total thrombotic and bleeding events in atrial fibrillation with stable coronary artery disease: a post hoc secondary analysis of the AFIRE trial. JAMA Cardiology. 2022; 7: 787–794.

[10] Yazaki Y, Nakamura M, Iijima R, Yasuda S, Kaikita K, Akao M, et al. Clinical outcomes of rivaroxaban monotherapy in heart failure patients with atrial fibrillation and stable coronary disease: insights from the AFIRE trial. Circulation. 2021; 144: 1449–1451.

[11] Matoba T, Yasuda S, Kaikita K, Akao M, Ako J, Nakamura M, et al. Rivaroxaban monotherapy in patients with atrial fibrillation after coronary stenting: insights from the AFIRE trial. JACC: Cardiovascular Interventions. 2021; 14: 2330–2340.

[12] Xiang Q, Wang Z, Mu G, Xie Q, Liu Z, Zhou S, et al. Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: a multicentre prospective cohort study. Clinical and Translational Medicine. 2023; 13: e1263.

[13] Weiss L, Keaney J, Szklanna PB, Prendiville T, Uhrig W, Wynne K, et al. Nonvalvular atrial fibrillation patients anticoagulated with rivaroxaban compared with warfarin exhibit reduced circulating extracellular vesicles with attenuated pro-inflammatory protein signatures. Journal of Thrombosis and Haemostasis. 2021; 19: 2583–2595.

[14] Coleman CI, Costa OS, Brescia CW, Vardar B, Abdelgawwad K, Sood N. Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin. Cardiovascular Diabetology. 2021; 20: 52.

[15] Methods in Medicine CAM. Retracted: effect of salvia miltiorrhiza polyphenolic acid injection on improving limb use and cognitive impairment in patients with acute stroke. Computational and Mathematical Methods in Medicine. 2023; 2023: 9787625.

[16] Wang Z, Zhu L, Yu L, Chen W, Chen Y, Li Q, et al. Real-world rivaroxaban use in fragile Asian patients with atrial fibrillation: the impact of plasma concentration on clinical outcomes. Thrombosis Research. 2022; 218: 189–191.

[17] Tittl L, Marten S, Naue C, Beyer-Westendorf J. 5-year outcomes from rivaroxaban therapy in atrial fibrillation: results from the Dresden NOAC registry. Thrombosis Research. 2021; 202: 24–30.

[18] Esteve-Pastor MA, Rivera-Caravaca JM, Roldán V, Sanmartin Fernández M, Arribas F, Masjuan J, et al. Predicting performance of the has-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: observations from the prospective EMIR Registry. European Heart Journal—Cardiovascular Pharmacotherapy. 2022; 9: 38–46.

[19] Arashi H, Yamaguchi J, Hagiwara N, Yasuda S, Kaikita K, Akao M, et al. Rivaroxaban underdose for atrial fibrillation with stable coronary disease: the AFIRE trial findings. Thrombosis and Haemostasis. 2022; 122: 1584–1593.

[20] Correction: risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban and effectiveness and safety of direct oral anticoagulants versus warfarin in patients with valvular atrial fibrillation. JACC: Cardiovascular Interventions. 2022; 175: 1627–1628.

[21] Liu X, Zhang Y, Ding H, Yan M, Jiao Z, Zhong M, et al. Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation. Acta Pharmacologica Sinica. 2022; 43: 2723–2734.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 1.0 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time

Conferences

Top